← Back to Search

Types of Radiation Therapy for Prostate Cancer

Phase 3
Waitlist Available
Led By Mark Buyyounouski
Research Sponsored by NRG Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adenocarcinoma of the prostate treated primarily with radical prostatectomy
No clinical evidence of regional lymph node metastasis
Must not have
Severe, active co-morbidity, defined as follows: Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months, Transmural myocardial infarction within the last 6 months, Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 1 registration, Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step 1 registration, Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease, Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol, End-stage renal disease (ie, on dialysis or dialysis has been recommended), Prior allergic reaction to the study drugs involved in this protocol, History of inflammatory bowel disease, prior bowel surgeries (or colostomy) for any reason, or prior partial/radical cystectomy for any reason
Neoadjuvant chemotherapy before or after prostatectomy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from randomization to last follow-up. maximum follow-up at time of analysis was 3.0 years.
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial compares two types of radiation therapy given after surgery to treat prostate cancer. One type delivers higher doses of radiation over a shorter period of time, and the other uses lower doses given over a longer period of time. Researchers want to see which type works better.

Who is the study for?
Men who've had prostate surgery for adenocarcinoma, with certain pathology results (pT2 or pT3), and no evidence of metastasis. They must have a PSA level < 2.0 ng/mL post-surgery, good performance status, and be able to complete questionnaires in English or French. Excluded are those with prior long-term hormone therapy, other recent cancers except non-melanoma skin cancer, severe health issues like heart failure or uncontrolled infections.
What is being tested?
The trial is comparing two types of radiation therapy after prostate surgery: hypofractionated (higher doses over a shorter period) versus conventional (standard doses over a longer period). The goal is to see which method is more effective at killing tumor cells with fewer side effects.
What are the potential side effects?
Radiation therapy may cause fatigue, skin irritation at the treatment site, frequent urination, discomfort during urination, rectal bleeding or irritation, erectile dysfunction and bowel changes such as diarrhea.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had surgery to remove my prostate cancer.
Select...
My cancer has not spread to nearby lymph nodes.
Select...
My cancer is classified as either pT2 or pT3.
Select...
My surgery showed cancer cells at the edge of the tissue removed.
Select...
My PSA level was below 2.0 ng/mL after my prostate surgery.
Select...
My scans show no bone metastases.
Select...
I speak English or French.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have received chemotherapy before or after surgery to remove my prostate.
Select...
I haven't had chemotherapy for another condition in the last 3 years.
Select...
My prostate cancer was stage pT2, surgery removed it all, and my PSA is under 0.1 ng/mL.
Select...
My lowest PSA level after prostate surgery was 0.2 or higher and my cancer is aggressive.
Select...
I've had radiation therapy in the same area as my current cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from randomization to last follow-up. maximum follow-up at time of analysis was 3.0 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from randomization to last follow-up. maximum follow-up at time of analysis was 3.0 years. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Bowel Domain of the Expanded Prostate Cancer Index (EPIC) at Two Years
Change in Urinary Domain of the Expanded Prostate Cancer Index (EPIC) at Two Years
Secondary study objectives
Change in Bowel Domain Score of the Expanded Prostate Cancer Index (EPIC) at End of RT, 6 Months, 1 and 5 Years
Change in Urinary Domain Score of the Expanded Prostate Cancer Index (EPIC) at End of Radiation Therapy (RT), 6 Months, 1 and 5 Years
Number of Participants With Grade 3+ Adverse Events
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Hypofractionated radiation therapyExperimental Treatment2 Interventions
Hypofractionated post-prostatectomy radiation therapy (HYPORT) over 5 weeks. Patients may also receive optional androgen deprivation therapy per doctor recommendation.
Group II: Conventional radiation therapyActive Control2 Interventions
Conventional post-prostatectomy radiation therapy (COPORT) over 7 weeks. Patients may also receive optional androgen deprivation therapy per doctor recommendation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hypofractionated radiation therapy
2009
Completed Phase 2
~150

Find a Location

Who is running the clinical trial?

NRG OncologyLead Sponsor
238 Previous Clinical Trials
102,795 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,938 Previous Clinical Trials
41,022,892 Total Patients Enrolled
Mark BuyyounouskiPrincipal InvestigatorNRG Oncology
1 Previous Clinical Trials
163 Total Patients Enrolled

Media Library

Hypofractionated radiation therapy Clinical Trial Eligibility Overview. Trial Name: NCT03274687 — Phase 3
Prostate Adenocarcinoma Research Study Groups: Conventional radiation therapy, Hypofractionated radiation therapy
Prostate Adenocarcinoma Clinical Trial 2023: Hypofractionated radiation therapy Highlights & Side Effects. Trial Name: NCT03274687 — Phase 3
Hypofractionated radiation therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT03274687 — Phase 3
~36 spots leftby Dec 2025